Stockscreener 앱 받기
1.08
1.89%
0.02
시간 외 거래:
1.10
0.02
+1.85%
전일 마감가:
$1.06
열려 있는:
$1.08
하루 거래량:
4.44M
Relative Volume:
0.78
시가총액:
$202.25M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-1.0093
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
+6.93%
1개월 성능:
-12.20%
6개월 성능:
-52.63%
1년 성능:
-78.14%
1일 변동 폭
$1.05
$1.12
1주일 범위
$0.91
$1.12
52주 변동 폭
$0.91
$5.33
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.08 | 198.51M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - marketscreener.com
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - marketscreener.com
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com UK
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryChart Pattern Recognition & Compound Your Gains With Quality Stocks - Bollywood Helpline
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Humacyte Reports High Limb Salvage Rates and Durability of Symvess in Long-Term Study Published in JVS-CIT - Quiver Quantitative
Off-the-shelf blood vessel implant helps save injured limbs in study - Stock Titan
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Regulatory Ruptures For A Lab-Grown Blood Vessel - The Lever
Lab-Grown Blood Vessel Maker Promotes Risky Off-Label Uses - Jacobin
Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - bolumsonucanavari.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Is Humacyte Inc. Equity Warrant stock a contrarian buy2025 Breakouts & Breakdowns & Safe Capital Growth Plans - DonanımHaber
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
Aug Chart Watch: Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterInsider Buying & Capital Efficient Trading Techniques - Улправда
Humacyte enters sales agreement with TD Securities - MSN
Humacyte's US$28m Market Cap Fall Books Insider Losses - simplywall.st
Humacyte’s Big Promise Still Faces A Rocky Road - Finimize
Humacyte Enters Sales Agreement with TD Securities - TipRanks
Humacyte may offer and sell shares of common stock of up to $60 million from time to time through TD Cowen, acting as agent - marketscreener.com
Humacyte (NASDAQ: HUMA) details $60M at the market stock offering - Stock Titan
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Investment Review: Is Humacyte Inc Equity Warrant stock a contrarian buyJuly 2025 Short Interest & Expert Curated Trade Setups - moha.gov.vn
Humacyte secures up to $77.5 million credit facility with Avenue Capital - Investing.com Nigeria
Humacyte secures $77.5 million loan facility - MSN
Humacyte announces credit facility of up to $77.5 million with Avenue Capital - marketscreener.com
Humacyte Signs $77.5 Million Credit Facility - marketscreener.com
Humacyte Secures $77.5 Million Credit Facility with Avenue Venture Opportunities Fund to Support Growth and Development Initiatives - Quiver Quantitative
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Humacyte, Inc. Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Total debt per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView — Track All Markets
Humacyte Secures $77.5 Million Loan Facility - TipRanks
[8-K] Humacyte, Inc. Reports Material Event | HUMA SEC FilingForm 8-K - Stock Titan
Humacyte terminates revenue interest purchase agreement - marketscreener.com
Humacyte Terminates Revenue Interest Agreement - TipRanks
Humacyte (NASDAQ: HUMA) to issue 5.7M shares, pay $38M to end deal - Stock Titan
Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to "Hold" - MarketBeat
Is Humacyte Inc a good long term investmentStraddle and Strangle Trades & Explosive Capital Growth Plans - earlytimes.in
Humacyte (HUMA): Benchmark remains bullish on stock - MSN
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):